Back to Search
MITCHIE DIAGO, M.D.
M.D.
Internal Medicine Physician
NPI: 1316120595Individual
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
233567(NY)
Research & Publications (20)
Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy.
PMID 19208349·Gastroenterology·2009
3-trial
Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks.
PMID 18710427·Liver Int·2009
8-other
Expression of cytokeratins in epithelialized periapical lesions.
PMID 19201226·Oral Surg Oral Med Oral Pathol Oral Radiol Endod·2009
8-other
Hospital admission is a relevant source of hepatitis C virus acquisition in Spain.
PMID 17998149·J Hepatol·2008
4-observational
Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C.
PMID 18308416·J Hepatol·2008
8-other
[Liver injury induced by "natural remedies": an analysis of cases submitted to the Spanish Liver Toxicity Registry].
PMID 19159172·Rev Esp Enferm Dig·2008
4-observational
Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C.
PMID 18098299·Hepatology·2008
8-other
[Treatment of hepatitis C virus infection: current status and perspectives].
PMID 19091249·Gastroenterol Hepatol·2008
6-review
Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype 1, treated with peginterferon-ribavirin.
PMID 18221912·J Clin Virol·2008
8-other
[Does antiviral therapy improve the clinical course of cirrhosis due to hepatitis C virus infection?].
PMID 17335716·Gastroenterol Hepatol·2007
8-other
Treatment of chronic he1patitis C genotype 1 with peginterferon-alpha2a (40 kDa) plus ribavirin under routine clinical practice in Spain: early prediction of sustained virological response rate.
PMID 17402993·Aliment Pharmacol Ther·2007
2-rct
Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients.
PMID 17894655·Aliment Pharmacol Ther·2007
2-rct
Induction doses of interferon-alpha-2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non-responders to interferon monotherapy: a randomized trial.
PMID 17244248·J Viral Hepat·2007
3-trial
The post-endodontic periapical lesion: histologic and etiopathogenic aspects.
PMID 18059244·Med Oral Patol Oral Cir Bucal·2007
6-review
Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.
PMID 17127704·Gut·2007
4-observational
Chronic hepatitis C in patients with persistently normal alanine transaminase levels.
PMID 16630770·Clin Gastroenterol Hepatol·2006
4-observational
Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin.
PMID 16792536·J Viral Hepat·2006
4-observational
Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.
PMID 16890599·Gastroenterology·2006
4-observational
Review article: management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity.
PMID 17014573·Aliment Pharmacol Ther·2006
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 10 ROCKEFELLER PLZ FL 4
NEW YORK, NY 10020 - Phone
- (212) 332-3700
Quick Facts
- NPI
- 1316120595
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile